Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer

Trial Profile

Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination With Pembrolizumab in Advanced Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Jan 2019

At a glance

  • Drugs FLX-475 (Primary) ; Pembrolizumab
  • Indications Adenocarcinoma; Advanced breast cancer; Cancer; Cervical cancer; Colorectal cancer; Gastric cancer; Head and neck cancer; Hodgkin's disease; Nasopharyngeal cancer; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Squamous cell cancer; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors FLX Bio
  • Most Recent Events

    • 05 Nov 2018 According to a FLX Bio media release, FLX Bio Announces Clinical Trial Collaboration Agreement with Merck for this study.
    • 27 Sep 2018 According to a FLX Bio media release, first patient has been treated in this trial.
    • 14 Sep 2018 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top